DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company's #FOBO (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/13/20 | $67,300,000 | Series A |
Johnson & Johnson Development Corporation (JJDC) Seventure Partners The Cove Fund True Wealth Ventures | undisclosed |
